Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...
SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, today announced the appointment of Chetan Pujara, Ph.D., as Chief Research & Development Officer. Dr. Pujara brings over 20 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback